A US Centers for Disease Control and Prevention panel on 23 September recommended a third or “booster” dose of Pfizer Inc./BioNTech SE’s Comirnaty COVID-19 vaccine for a broad swath of the American public, including those age 65 years and older or with comorbid medical conditions, but failed to support use for health care workers and others at risk for occupational exposure.
The Advisory Committee on Immunization Practices’ interim recommendations for a booster dose came in a complicated series of votes at
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?